146 related articles for article (PubMed ID: 11260006)
21. A long-term multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis.
Langner A; Ashton P; Van De Kerkhof PC; Verjans H
Br J Dermatol; 1996 Sep; 135(3):385-9. PubMed ID: 8949430
[TBL] [Abstract][Full Text] [Related]
22. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting.
van de Kerkhof PC; van der Valk PG; Swinkels OQ; Kucharekova M; de Rie MA; de Vries HJ; Damstra R; Oranje AP; de Waard-van der Spek FB; van Neer P; Lijnen RL; Kunkeler AC; van Hees C; Haertlein NG; Hol CW
Br J Dermatol; 2006 Oct; 155(4):800-7. PubMed ID: 16965431
[TBL] [Abstract][Full Text] [Related]
23. Double-blind, placebo-controlled, randomized, right-left study comparing calcipotriol monotherapy with a combined treatment of calcipotriol and diflucortolone valerate in chronic plaque psoriasis.
Salmhofer W; Maier H; Soyer HP; Hönigsmann H; Hödl S
Acta Derm Venereol Suppl (Stockh); 2000; (211):5-8. PubMed ID: 11234559
[TBL] [Abstract][Full Text] [Related]
24. The safety of calcitriol 3 microg/g ointment. Evaluation of cutaneous contact sensitization, cumulative irritancy, photoallergic contact sensitization and phototoxicity.
Queille-Roussel C; Duteil L; Parneix-Spake A; Arsonnaud S; Rizova E
Eur J Dermatol; 2001; 11(3):219-24. PubMed ID: 11358728
[TBL] [Abstract][Full Text] [Related]
25. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group.
Highton A; Quell J
J Am Acad Dermatol; 1995 Jan; 32(1):67-72. PubMed ID: 7822519
[TBL] [Abstract][Full Text] [Related]
26. Topical use of calcitriol 3 microg/g ointment in the treatment of mild-to-moderate psoriasis: results from an open-label study.
Carboni I; de Felice C; Bergamin A; Chimenti S
J Eur Acad Dermatol Venereol; 2005 Nov; 19 Suppl 3():11-3. PubMed ID: 16274406
[TBL] [Abstract][Full Text] [Related]
27. 26,27-Hexafluoro-1,25-dihydroxyvitamin D3 (F6-1,25(OH)2D3) prevents osteoporosis induced by immobilization combined with ovariectomy in the rat.
Okumura H; Yamamuro T; Higuchi S; Harada M; Takamura T; Otomo S; Aihara H; Ikekawa N; Kobayashi T
Bone Miner; 1990 May; 9(2):101-9. PubMed ID: 2350614
[TBL] [Abstract][Full Text] [Related]
28. Induction of vitamin D receptor mRNA expression in psoriatic plaques correlates with clinical response to 1,25-dihydroxyvitamin D3.
Chen ML; Perez A; Sanan DK; Heinrich G; Chen TC; Holick MF
J Invest Dermatol; 1996 Apr; 106(4):637-41. PubMed ID: 8617997
[TBL] [Abstract][Full Text] [Related]
29. Topical becocalcidiol for the treatment of psoriasis vulgaris: a randomized, placebo-controlled, double-blind, multicentre study.
Helfrich YR; Kang S; Hamilton TA; Voorhees JJ
Br J Dermatol; 2007 Aug; 157(2):369-74. PubMed ID: 17596167
[TBL] [Abstract][Full Text] [Related]
30. Long-term safety and efficacy of high-concentration (20 microg/g) tacalcitol ointment in psoriasis vulgaris.
Miyachi Y; Ohkawara A; Ohkido M; Harada S; Tamaki K; Nakagawa H; Hori Y; Nishiyama S
Eur J Dermatol; 2002; 12(5):463-8. PubMed ID: 12370136
[TBL] [Abstract][Full Text] [Related]
31. Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis.
Guzzo C; Lazarus G; Goffe BS; Katz HI; Lowe NJ; Pincus SH
J Am Acad Dermatol; 1996 Mar; 34(3):429-33. PubMed ID: 8609254
[TBL] [Abstract][Full Text] [Related]
32. Calcipotriol: a new drug for topical psoriasis treatment.
Kragballe K
Pharmacol Toxicol; 1995 Oct; 77(4):241-6. PubMed ID: 8577633
[TBL] [Abstract][Full Text] [Related]
33. Topical paricalcitol (19-nor-1 alpha,25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study.
Durakovic C; Ray S; Holick MF
Br J Dermatol; 2004 Jul; 151(1):190-5. PubMed ID: 15270890
[TBL] [Abstract][Full Text] [Related]
34. Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebo-controlled clinical trial.
Woo WK; McKenna KE
Br J Dermatol; 2003 Jul; 149(1):146-50. PubMed ID: 12890208
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerance of topical calcitriol 3 microg g(-1) in psoriasis treatment: a review of our experience in Poland.
Langner A; Stapór W; Ambroziak M
Br J Dermatol; 2001 Apr; 144 Suppl 58():11-6. PubMed ID: 11501507
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of the 20-epi-vitamin D3 analogue KH 1060 in the topical therapy of psoriasis: results of a dose-ranging study.
Kragballe K; Dam TN; Hansen ER; Baadsgaard O; Grønhøj Larsen F; Søndergaard J; Axelsen MB
Acta Derm Venereol; 1994 Sep; 74(5):398-402. PubMed ID: 7817684
[TBL] [Abstract][Full Text] [Related]
37. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis.
Tirado-Sánchez A; Ponce-Olivera RM
Cutis; 2012 Sep; 90(3):140-4. PubMed ID: 23094314
[TBL] [Abstract][Full Text] [Related]
38. Calcium homeostasis remains unaffected after 12 weeks' therapy with calcitriol 3 microg/g ointment; no correlation with extent of psoriasis.
Barker JN; Berth-Jones J; Groves R; Omerod AD; Rizova E; Griffiths CE
J Dermatolog Treat; 2003 Jan; 14(1):14-21. PubMed ID: 12745850
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group.
Molin L; Cutler TP; Helander I; Nyfors B; Downes N
Br J Dermatol; 1997 Jan; 136(1):89-93. PubMed ID: 9039301
[TBL] [Abstract][Full Text] [Related]
40. Comparative evaluation of topical calcipotriol versus coal tar and salicylic acid ointment in chronic plaque psoriasis.
Singh P; Gupta S; Abidi A; Krishna A
J Drugs Dermatol; 2013 Aug; 12(8):868-73. PubMed ID: 23986159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
